GLYATL1B

Summary

GLYATL1B (glycine-N-acyltransferase like 1B, HGNC:37865) is a protein-coding gene on chromosome 11q12.1, encoding Putative glycine N-acyltransferase-like protein 1B (A0A0U1RQE8). Putative acyltransferase which transfers an acyl group to the N-terminus of glutamine.

Predicted to enable glutamine N-acyltransferase activity. Predicted to be involved in glutamine metabolic process. Predicted to be located in mitochondrion.

Source: NCBI Gene 100287520 — RefSeq curated summary.

At a glance

• MANE Select transcript: NM_001355566

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:37865
Approved symbol	GLYATL1B
Name	glycine-N-acyltransferase like 1B
Location	11q12.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000255151
Ensembl biotype	protein_coding
Entrez	100287520

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000527482

RefSeq mRNA: 1 — MANE Select: NM_001355566 NM_001355566

CCDS: CCDS86204

Canonical transcript exons

ENST00000527482 — 5 exons

Exon	Start	End
ENSE00002162451	59086307	59086384
ENSE00002465876	59094369	59094786
ENSE00002496150	59093529	59093655
ENSE00002497235	59087064	59087171
ENSE00002509664	59093934	59094111

Expression profiles

Bgee: expression breadth broad, 18 present calls, max score 47.65.

Top tissues by expression

121 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
vermiform appendix	UBERON:0001154	47.65	gold quality
tonsil	UBERON:0002372	47.63	gold quality
lymph node	UBERON:0000029	46.89	gold quality
cortical plate	UBERON:0005343	45.97	gold quality
granulocyte	CL:0000094	41.44	silver quality
ventricular zone	UBERON:0003053	40.70	gold quality
bone marrow cell	CL:0002092	38.61	gold quality
minor salivary gland	UBERON:0001830	38.40	gold quality
saliva-secreting gland	UBERON:0001044	37.98	gold quality
ganglionic eminence	UBERON:0004023	37.62	silver quality
colonic epithelium	UBERON:0000397	37.20	gold quality
mucosa of transverse colon	UBERON:0004991	36.67	gold quality
sural nerve	UBERON:0015488	36.10	gold quality
skeletal muscle tissue	UBERON:0001134	33.38	gold quality
bone marrow	UBERON:0002371	33.00	gold quality
blood	UBERON:0000178	32.47	gold quality
hindlimb stylopod muscle	UBERON:0004252	32.15	gold quality
spleen	UBERON:0002106	31.61	gold quality
small intestine Peyer’s patch	UBERON:0003454	31.42	gold quality
small intestine	UBERON:0002108	31.21	silver quality
prostate gland	UBERON:0002367	31.21	silver quality
muscle tissue	UBERON:0002385	31.06	gold quality
stromal cell of endometrium	CL:0002255	29.87	gold quality
prefrontal cortex	UBERON:0000451	29.60	gold quality
thoracic mammary gland	UBERON:0005200	29.13	silver quality
gall bladder	UBERON:0002110	29.04	silver quality
duodenum	UBERON:0002114	28.14	gold quality
rectum	UBERON:0001052	27.92	silver quality
leukocyte	CL:0000738	26.99	gold quality
skin of abdomen	UBERON:0001416	26.58	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.45

Regulation

Is transcription factor: no

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	si:dkey-76k16.5	ENSDARG00000075561
danio_rerio	si:dkey-76k16.6	ENSDARG00000077481
danio_rerio	si:ch73-106k19.2	ENSDARG00000102568
caenorhabditis_elegans		WBGENE00011681
caenorhabditis_elegans		WBGENE00018400
caenorhabditis_elegans		WBGENE00022683

Paralogs (4): GLYAT (ENSG00000149124), GLYATL2 (ENSG00000156689), GLYATL1 (ENSG00000166840), GLYATL3 (ENSG00000203972)

Protein

Protein identifiers

Putative glycine N-acyltransferase-like protein 1B — A0A0U1RQE8 (reviewed: A0A0U1RQE8)

All UniProt accessions (1): A0A0U1RQE8

UniProt curated annotations — full annotation on UniProt →

Function. Putative acyltransferase which transfers an acyl group to the N-terminus of glutamine. Can use phenylacetyl-CoA as an acyl donor.

Similarity. Belongs to the glycine N-acyltransferase family.

RefSeq proteins (1): NP_001342495* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR010313	Glycine_N-acyltransferase	Family
IPR013652	Glycine_N-acyltransferase_C	Domain
IPR015938	Glycine_N-acyltransferase_N	Domain
IPR016181	Acyl_CoA_acyltransferase	Homologous_superfamily

Pfam: PF06021, PF08444

Catalyzed reactions (Rhea), 1 shown:

• an acyl-CoA + L-glutamine = an N(2)-acyl-L-glutamine + CoA + H(+) (RHEA:18469)

UniProt features (1 total): chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-A0A0U1RQE8-F1	90.28	0.74

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 13 (showing top): GOBP_ALPHA_AMINO_ACID_METABOLIC_PROCESS, GOBP_GLUTAMINE_FAMILY_AMINO_ACID_METABOLIC_PROCESS, GOBP_GLUTAMINE_METABOLIC_PROCESS, GOBP_ORGANIC_ACID_METABOLIC_PROCESS, GOMF_ACYLTRANSFERASE_ACTIVITY, GOMF_N_ACYLTRANSFERASE_ACTIVITY, GOMF_GLYCINE_N_ACYLTRANSFERASE_ACTIVITY, GOBP_SMALL_MOLECULE_METABOLIC_PROCESS, GOMF_ACYLTRANSFERASE_ACTIVITY_TRANSFERRING_GROUPS_OTHER_THAN_AMINO_ACYL_GROUPS, GOBP_L_AMINO_ACID_METABOLIC_PROCESS, chr11q12, GOCC_MITOCHONDRION, GOBP_AMINO_ACID_METABOLIC_PROCESS

GO Biological Process (1): L-glutamine metabolic process (GO:0006541)

GO Molecular Function (4): L-glutamine N-acyltransferase activity (GO:0047946), glycine N-acyltransferase activity (GO:0047961), transferase activity (GO:0016740), acyltransferase activity (GO:0016746)

GO Cellular Component (1): mitochondrion (GO:0005739)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
L-amino acid metabolic process	1
proteinogenic amino acid metabolic process	1
L-amino-acid N-acetyltransferase activity	1
amino acid acyltransferase activity	1
catalytic activity	1
transferase activity	1
cytoplasm	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

366 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GLYATL1B	ACSM2B	Q68CK6	389
GLYATL1B	SUOX	P51687	350
GLYATL1B	AMT	P48728	318
GLYATL1B	NAGS	Q8N159	286
GLYATL1B	GAMT	Q14353	251
GLYATL1B	CKMT1B	P12532	228
GLYATL1B	CKMT2	P17540	227
GLYATL1B	CAD	P27708	226
GLYATL1B	ASL	P04424	222
GLYATL1B	OTC	P00480	209
GLYATL1B	CCNH	P51946	209
GLYATL1B	CKB	P12277	202
GLYATL1B	GATM	P50440	197
GLYATL1B	DHX16	O60231	196
GLYATL1B	CKM	P06732	191

IntAct

0 interactions, top by confidence:

ESM2 similar proteins: A0A0U1RQE8, F1S5L4, O43010, O77512, P06592, P13233, P14714, P42498, P49895, P55004, P97564, Q07071, Q09305, Q0P464, Q0P4Y1, Q1LYL8, Q2KHV5, Q2KIR7, Q3UW68, Q5BK10, Q5FW57, Q5GJ77, Q5PQT3, Q5RFP0, Q60462, Q61586, Q62240, Q64112, Q6IB77, Q6MZZ7, Q6P5U7, Q6QN13, Q6QR59, Q6V915, Q7L7V1, Q804E1, Q8CBA2, Q8T773, Q8WU03, Q91754

Diamond homologs: A0A0U1RQE8, E9Q5L8, O77512, Q2KIR7, Q5FW57, Q5PQT3, Q5RFP0, Q5SZD4, Q6IB77, Q8WU03, Q91XE0, Q969I3, Q9DCY0, Q9Z2Y0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

0 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

890 predictions. Top by Δscore:

Variant	Effect	Δscore
11:59086391:G:GT	donor_gain	0.9900
11:59086392:A:T	donor_gain	0.9900
11:59087063:GGT:G	acceptor_gain	0.9900
11:59087167:AACAG:A	donor_loss	0.9900
11:59087168:ACAG:A	donor_loss	0.9900
11:59087169:CAGGT:C	donor_loss	0.9900
11:59087170:AGGT:A	donor_loss	0.9900
11:59087171:GGTAG:G	donor_loss	0.9900
11:59087172:G:A	donor_loss	0.9900
11:59087173:T:G	donor_loss	0.9900
11:59088368:T:G	acceptor_gain	0.9900
11:59086380:TGAAG:T	donor_loss	0.9800
11:59086383:AG:A	donor_loss	0.9800
11:59086384:GGTG:G	donor_loss	0.9800
11:59086385:G:C	donor_loss	0.9800
11:59086386:T:G	donor_loss	0.9800
11:59087059:TTCAG:T	acceptor_loss	0.9800
11:59087060:TCAGG:T	acceptor_loss	0.9800
11:59087061:CAG:C	acceptor_loss	0.9800
11:59087062:A:G	acceptor_loss	0.9800
11:59087063:G:T	acceptor_loss	0.9800
11:59094368:GC:G	acceptor_gain	0.9800
11:59086400:G:T	donor_gain	0.9700
11:59094365:ACAGC:A	acceptor_gain	0.9700
11:59094366:C:G	acceptor_gain	0.9700
11:59094367:A:AG	acceptor_gain	0.9700
11:59094368:G:GG	acceptor_gain	0.9700
11:59094368:GCGA:G	acceptor_gain	0.9700
11:59088367:AT:A	acceptor_gain	0.9600
11:59088372:C:G	acceptor_gain	0.9600

AlphaMissense

1988 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:59093574:T:C	F78L	0.965
11:59093576:C:A	F78L	0.965
11:59093576:C:G	F78L	0.965
11:59087103:T:C	F40L	0.923
11:59087105:C:A	F40L	0.923
11:59087105:C:G	F40L	0.923
11:59087130:T:A	W49R	0.912
11:59087130:T:C	W49R	0.912
11:59094535:T:A	W220R	0.910
11:59094535:T:C	W220R	0.910
11:59094751:T:A	W292R	0.895
11:59094751:T:C	W292R	0.895
11:59093633:G:C	W97C	0.888
11:59093633:G:T	W97C	0.888
11:59087158:G:C	R58P	0.886
11:59094753:G:C	W292C	0.876
11:59094753:G:T	W292C	0.876
11:59093650:T:C	I103T	0.871
11:59086384:G:C	K26N	0.865
11:59086384:G:T	K26N	0.865
11:59093631:T:A	W97R	0.858
11:59093631:T:C	W97R	0.858
11:59094457:A:C	S194R	0.853
11:59094459:C:A	S194R	0.853
11:59094459:C:G	S194R	0.853
11:59094537:G:C	W220C	0.839
11:59094537:G:T	W220C	0.839
11:59087132:G:C	W49C	0.834
11:59087132:G:T	W49C	0.834
11:59094661:T:C	F262L	0.834

dbSNP variants (sampled 300 via entrez): RS1000515424 (11:59091832 T>C,G), RS1000683163 (11:59087016 A>G), RS1000755240 (11:59087193 G>A,C), RS1001566706 (11:59086704 T>C), RS1002066078 (11:59091531 C>A), RS1002121253 (11:59086370 C>T), RS1002539750 (11:59091737 T>C), RS1002686641 (11:59088822 T>A), RS1003038691 (11:59094483 A>C,G,T), RS1003219405 (11:59085519 A>G), RS1003812281 (11:59090369 G>A), RS1004140670 (11:59091190 G>C,T), RS1004142217 (11:59090235 A>G), RS1005055216 (11:59087449 T>C,G), RS1005130357 (11:59092716 A>G,T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.